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LETTER TO THE EDITOR
Colorectal Cancer Risk in Monoallelic Carriers
of MYH Variants
To the Editor: Since low-frequency variants in the base-
excision-repair gene MYH (MIM 604933) were first dem-
onstrated to confer a recessive colorectal cancer (CRC)
risk,1,2 there has been speculation of an additional dom-
inant effect.3,4 In a recent article, Farrington et al.5 de-
scribed the results of screening a series of 2,239 CRC cases
and 1,845 controls for germline variants in the human
homolog of the Escherichia coli muty gene (MYH). In
whites, Y165C and G382D are the principal disease-caus-
ing variants of MYH. Among the cases, Farrington et al.5
detected 46 monoallelic carriers of these variants (14
Y165C heterozygotes and 32 G382D heterozygotes) and
11 biallelic carriers (8 G382D homozygotes and 3 com-
pound heterozygotes), with corresponding frequencies
among the controls of 28 monoallelic carriers and 0 bial-
lelic carriers. They employed the method of Hugot et al.6
to estimate the genotype relative risk (GRR) associated
with biallelic and monoallelic variant carriers. Their study
confirmed the well-established increased risk of CRC in
biallelic carriers of variants inMYH ( ; 95%CIGRRp 92.65
41.60–213.20). Although they did not find a statistically
significant increased risk for monoallelic variant carriers
( ; 95% CI 0.92–2.07), the authors suggestedGRRp 1.35
that MYH heterozygosity might be associated with an el-
evated CRC risk—primarily in later life—after they arbi-
trarily restricted their analysis to cases of CRC diagnosed
after age 55 years ( ; 95% CI 1.07–2.95).GRRp 1.68
We believe that such a conclusion may be premature.
First, the GRR calculation approach employed is not nec-
essary for assessment of risk associated with heterozygote
variant carriers. Moreover, other analytical approaches, in-
cluding the standard asymptotic approach and exact ap-
proaches, yield 95% CIs that do not exclude an odds ratio
(OR) of 1. Second, the type of stratification employed
raises the issue of post hoc analysis. Third, we have sim-
ilarly determined the frequencies of Y165C and G382D in
a large case-control study and findno evidence thatmono-
allelic MYH variant status influences CRC risk.
Our analysis was based on a series of 2,561 patients with
histologically confirmed colorectal adenocarcinomas
(1,474 males and 1,087 females; mean  SD age at di-
agnosis 61 11.4 years) ascertained through an ongoing
initiative at the Institute of Cancer Research/Royal Mars-
den Hospital National Health Service Trust. We previously
reported MYH results for a subset of 358 of these cases.4
A total of 2,695 control individuals (836 males and 1,859
females; mean SD age 59 10.9 years) were the spouses
of patients with malignancies, recruited as part of the Na-
tional Cancer Research Network Trial (1999–2002), the
Royal Marsden Hospital Trust/Institute of Cancer Research
Family History and DNA Registry (1999–2004), the Na-
tional Study of Colorectal Cancer Genetics Trial (2004),
or the UK Study of Breast Cancer Genetics, all established
within the United Kingdom. None of the controls had a
personal history of malignancy at the time of ascertain-
ment. All cases and controls were British whites, and there
were no obvious differences in the demography of cases
and controls in terms of place of residence within the
United Kingdom. Blood samples were obtained with in-
formed consent and ethics review board approval, in ac-
cordance with the tenets of the Declaration of Helsinki.
Genotyping of Y165C and G382D was performed using
customized Illumina Sentrix Bead Arrays in accordance
with the manufacturer’s protocols. Assay validation was
conducted using TaqMan and by direct sequencing of a
subset of samples.
Among the patients with CRC, we identified 4 individ-
uals with biallelic variants (1 G382D homozygote and 3
compound heterozygotes) and 53 with monoallelic vari-
ants (38 G382D heterozygotes and 15 Y165C heterozy-
gotes). Among controls, no biallelic variants were iden-
tified, but 57 monoallelic variant carriers were identified
(40 with G382D and 17 with Y165C). For each SNP, ge-
notype distributions among controls did not deviate sig-
nificantly from Hardy-Weinberg equilibrium (exact Pp
). These frequencies of MYH variants are comparable1.0
to those documented in other populations—specifically
those from the United Kingdom–based series reported by
Farrington et al.5 ( for controls; for cases)Pp .17 Pp .97
(table 1)—and translate to risks of 5.57 (95% CI 0.69–)
and 0.98 (95% CI 0.66–1.46) associated with biallelic and
monoallelic carrier status, respectively. Stratificationof the
data by 10-year age bands provided no evidence that risk
associated with monoallelic carrier status was influenced
by age ( ). Furthermore, after the data were parti-Pp .13
tioned, as by Farrington et al.,5 risks associated with early-
and late-onset disease were comparable (for age at onset
55 years, OR 0.83; 95% CI 0.42–1.51; for age at onset
155 years, OR 1.03; 95% CI 0.66–1.58).
To further explore the possibility that monoallelic var-
iant status might affect CRC, we applied a kin-cohort ap-
proach to compare risks in the 14,668 first-degree relatives
of carriers and noncarriers. Data on history of any type
of cancer, including age at diagnosis as well as vital status
and current age or age at death, were collected for parents,
siblings, and offspring by a previously validated question-
naire. Fourteen (4.3%) of the 324 relatives of variant car-
riers and 431 (3.0%) of the 14,344 relatives of noncarriers
had received a diagnosis of CRC. Age-specific cumulative
CRC distributions in first-degree relatives were estimated
using a marginal-likelihood approach,7 and bootstrap es-
timates for the hazard ratios (HRs) were used to calculate
95% CIs. The HR generated from this analysis for CRC
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Table 1. Summary of Published Case-Control Studies of the Relationship between MYH Variants
Y165C and G382D and Risk of CRC
Study and
Ethnicity Place of Study
Cases Controls
n
No. (%) of
Monoallelic
Carriers
No. (%) of
Biallelic
Carriers n
No. (%) of
Monoallelic
Carriers
No. (%) of
Biallelic
Carriers
Croitoru et al.3,a Ontario 1,238 32 (2.6) 9 (.7) 1,255 21 (1.7) 0 (0)
Farrington et al.5,b Scotland 2,217 46 (2.1) 11 (.5) 1,822 28 (1.5) 0 (0)
Enholm et al.8,c Finland 1,003 5 (.5) 4 (.4) 424 0 (0) 0 (0)
Kambara et al.9,d Brisbane, Australia 92 2 (2.2) 0 (0) 53 1 (1.9) 0 (0)
Wang et al.10,e Minnesota 444 10 (2.3) 2 (.5) 313 4 (1.3) 0 (0)
Peterlongo et al.11,f:
All ethnicities New York 555 4 (.7) 2 (.4) 918 7 (.8) 0 (0)
White New York 244 4 (1.6) 2 (.8) 366 6 (1.6) 0 (0)
Jewish New York 266 0 (0) 0 (0) 450 0 (0) 0 (0)
Zhou et al.12,g Sweden 438 6 (1.4) 0 (0) 469 3 (.6) 0 (0)
Present study:
White United Kingdom 2,561 53 (2.1) 4 (.2) 2,695 57 (2.1) 0 (0)
a Cases were aged 20–74 years; study included age- and sex-matched population controls.
b Of the cases, 872 were !55 years old at diagnosis; study included age- and sex-matched population-based controls.
c Study included unselected cases (mean  SD age at diagnosis 67.2  12.1 years) and blood-donor controls.
d Mean  SD age of cases was 69.1  10.6 years; study included blood-donor controls.
e Of the cases, 116 were !50 years old at diagnosis; controls were taken from among individuals undergoing screening
colonoscopy with no evidence of adenomatous polyps.
f Mean age of cases was 62.2 years; study included population-based controls matched by age (mean age 55.0 years),
ethnicity, and religious group.
g Study included sporadic CRC cases and blood-donor controls.
associated with monoallelic variant status was 1.74 (95%
CI 0.62–3.60).
To date, seven published studies have reported the fre-
quency of Y165C and G382D MYH variants in CRC cases
and controls3,5,8–12 (table 1 and fig. 1). Collectively, these
provide information on the frequency ofMYH variants in
8,546 cases and 7,949 controls. To further quantify the
risks associated with MYH status, we performed a pooled
analysis of these published studies with our data. ORswere
calculated for each study by use of exact logistic regres-
sion, since five of the studies contained !5 individuals in
a single category. Meta-analysis was conducted using stan-
dard methods for combining estimates of ORs based on
the weighted sum of the log estimates, with the inverse
of the variance of the estimate as the weight. An exact
conditional-likelihood approach13 was used to obtain a
95% CI for the pooled OR. There was no significant evi-
dence of heterogeneity between studies (Cochran’s Qp
; ); however, we used both fixed- and random-3.74 Pp .81
effects models to combine study results. Under the fixed-
effects model, the pooled OR for monoallelic carrier status
was 1.26 (95% CI 0.99–1.60), whereas, under the random-
effects model, the pooled OR was 1.24 (95%CI 0.98–1.59).
The risk associated with biallelic carrier status is not finite
because there is no representation in controls, but an exact
approach yields a lower 95% confidence bound of 7.39
for the risk estimate. Alternatively, a naive approach based
on the convention of adding 0.5 to each empty cell gen-
erates a risk estimate of 6.06 (95% CI 2.02–18.19). Al-
though this analysis provides robust evidence that carriers
of biallelic MYH variants are at a significantly increased
risk of CRC, the data do not indicate a statistically sig-
nificant excess of MYH carriers among CRC cases com-
pared with among controls. Our estimate of the risk as-
sociated with monoallelic carrier status is, in fact, likely
to be inflated, since we restricted our analysis to the path-
ogenic MYH variants Y165C and G382D and since some
individuals heterozygous for these variants may carry ad-
ditional pathogenic variants. Hence, it is likely that ad-
ditional, apparently heterozygous cases will, in reality, be
compound heterozygotes. For example, in the studies by
Croitoru et al.3 and Farrington et al.,5 some cases hetero-
zygous for Y165C or G382D carried additional rare vari-
ants (three cases and one case, respectively). With our
analysis adjusted for these observations, the pooled OR
associated with monoallelic variant status is 1.23 (95% CI
0.96–1.58).
Our analysis of quantifying the CRC risk associatedwith
carriers of monoallelic MYH variants illustrates an inher-
ent problem in studying low-penetrance variants. By def-
inition, such alleles are not associated with large risks. If
the population frequency of an at-risk genotype is low
(i.e., !2%), then exceptionally large studies are required
to estimate precisely the risks. For example, to detect com-
prehensively the relative risk of 1.2 would require 22,000
cases and 22,000 controls. In conclusion, we believe that
the assertion that monoallelic carrier status for MYH var-
iants confers an elevated risk of CRC is unsupported on
the basis of current data.
EMILY L. WEBB, MATHEW F. RUDD,
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Figure 1. Funnel plot of OR of CRC risk associated with monoallelic Y165C and G382D MYH variants, under a fixed-effects model.
Studies are plotted in order of decreasing variance of the log(OR). Horizontal lines represent 95% CIs. Each box represents the OR point
estimate, and its area is proportional to the weight of the study. The diamond and broken line represent the overall summary estimate,
with the 95% CI given by the width of the diamond. The unbroken vertical line is at the null value (OR 1.0).
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MYH)
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